Signaturefd LLC Acquires 92 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Signaturefd LLC raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 40.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 319 shares of the medical equipment provider’s stock after acquiring an additional 92 shares during the period. Signaturefd LLC’s holdings in Lantheus were worth $35,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Lantheus by 0.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after acquiring an additional 100 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 146 shares during the period. Moody National Bank Trust Division raised its holdings in Lantheus by 1.1% in the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock valued at $1,203,000 after buying an additional 162 shares during the last quarter. Finally, Retirement Systems of Alabama boosted its position in Lantheus by 0.3% during the 1st quarter. Retirement Systems of Alabama now owns 86,005 shares of the medical equipment provider’s stock worth $5,353,000 after buying an additional 226 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 10,481 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the transaction, the director now directly owns 454,923 shares of the company’s stock, valued at approximately $43,445,146.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the sale, the president now owns 98,980 shares in the company, valued at $9,540,682.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mary Anne Heino sold 10,481 shares of the firm’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the completion of the transaction, the director now directly owns 454,923 shares in the company, valued at approximately $43,445,146.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,981 shares of company stock valued at $2,689,156 over the last ninety days. 1.50% of the stock is owned by corporate insiders.

Lantheus Stock Down 0.6 %

Shares of NASDAQ:LNTH opened at $109.38 on Thursday. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The business’s 50-day moving average is $107.80 and its 200-day moving average is $93.85. The company has a market capitalization of $7.58 billion, a price-to-earnings ratio of 16.83 and a beta of 0.50.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. During the same quarter in the previous year, the company posted $1.40 earnings per share. Lantheus’s quarterly revenue was up 22.5% on a year-over-year basis. Equities research analysts predict that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Analysts Set New Price Targets

LNTH has been the subject of several analyst reports. Leerink Partners raised their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Redburn Atlantic initiated coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. JMP Securities reduced their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. B. Riley increased their price target on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, Truist Financial cut their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.